Staidson (Beijing) BioPharmaceuticals Co., Ltd. (300204.SZ) SHZ

33.36

-0.51(-1.51%)

Updated at September 29 10:34AM

Currency In CNY

Staidson (Beijing) BioPharmaceuticals Co., Ltd.

Address

No. 36, Jinghai Er Road

Beijing, 100176

China

Phone

86 10 6751 9888

Sector

Healthcare

Industry

Biotechnology

Employees

555

First IPO Date

April 15, 2011

Key Executives

NameTitlePayYear Born
Mr. Maorong YuSecretary of the Board & Deputy GM01981
Mr. Shicheng Li CPAHead of Accounting & Financial Director01982
Mr. Wang ChaoGeneral Manager01982

Description

Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research and development, production, and marketing of therapeutic drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; gene therapy/cell therapy drugs; and chemical drugs. It principally offers its products under the fields of nervous system related, infectious, gastrointestinal, urinary system, and autoimmune diseases. The company has a strategic collaboration with Pivotal S.L. to assess BDB-001, a monoclonal anti-C5a antibody, in a clinical trial in Europe in progressive severe COVID-19 patients caused by SARS-CoV-2. Staidson (Beijing) BioPharmaceuticals Co., Ltd. was founded in 2002 and is based in Beijing, China.